| Systematic (IUPAC) name | |
|---|---|
| (RS)-5-[1-hydroxy-2-(isopropylamino)ethyl]benzene-1,3-diol | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a682084 |
| Pregnancy cat. | A(AU) C(US) |
| Legal status | ℞-only (US) |
| Routes | Inhalation / tablets |
| Pharmacokinetic data | |
| Bioavailability | 3% if inhaled, 40% if taken orally |
| Metabolism | Gastrointestinal and hepatic |
| Half-life | 6 hours |
| Identifiers | |
| CAS number | 586-06-1 |
| ATC code | R03AB03 R03CB03 R03CB53 |
| PubChem | CID 4086 |
| DrugBank | DB00816 |
| ChemSpider | 3944 |
| UNII | 53QOG569E0 |
| KEGG | D08300 |
| ChEMBL | CHEMBL776 |
| Chemical data | |
| Formula | C11H17NO3 |
| Mol. mass | 211.258 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| Physical data | |
| Solubility in water | 9.7 mg/mL (20 °C) |
| (what is this?) (verify) |
|
Orciprenaline (INN, also known as metaproterenol) is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective beta2-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. The pharmacologic effects of beta adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.